• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
By JAMES PASSERI Oct 28, 2016 | 03:04 PM EDT
Stocks quotes in this article: VRX, MCK, PRGO, MYL

Valeant Pharmaceuticals' (VRX)  shareholders were running for the hills Friday after San Francisco-based McKesson  (MCK) pharmaceutical distributor announced a competitor is "significantly" undercutting drug prices. (Valeant is a member of Real Money's Stressed Out watch list.)

"What we began to see more recently is competitive activity that is broader than our original expectations, more aggressive, and across several areas of our U.S. pharmaceutical business," McKesson CEO John Hammergren said on an earnings call with analysts. "When a competitor significantly undercuts our existing pricing, we are compelled to respond," he added, without disclosing which among its competitors have been slashing prices the most.

Shares of Valeant, which is laden with roughly $31 billion in debt and slated to roll out earnings Nov. 8, fell roughly 6% in afternoon trading following Hammergren's comments. 

The Canadian based drugmaker has been among the most embroiled in controversy over drug prices, especially after Democratic presidential candidate Hillary Clinton attacked the company for "predatory pricing" strategies and "gouging" patients by raising prices on acquired drugs.

And the industry has broadly found itself under renewed pressure to reduce drug prices on the back of increased regulatory and media scrutiny, especially following the controversy over the exorbitantly raised prices on Mylan's (MYL)  anti-allergy EpiPen product.

Valeant shares are now down about 80% on the year, amid the controversy surrounding price hikes on products acquired over years of debt-fueled acquisitions that led to the replacement of its CEO Michael Pearson with former Perrigo  (PRGO) CEO Joseph Papa. Valeant's problems were compounded by an SEC probe into its former partnership with mail-order pharmacy Philidor, in which Valeant acknowledged that $58 million worth of revenue was booked improperly, as well as the delay of its annual and first-quarter filings with the Securities and Exchange Commission.

Shares of McKesson were also down about 25% on CEO Hammergren's comments and the company's fiscal second-quarter earnings whiff.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login